Clinical Trial Update: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial results report safety, pharmacokinetics, and pharmacodynamics of garadacimab in idiopathic pulmonary fibrosis. The study is completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Garadacimab (garadacimab)

Snippet

Sponsor: CSL Behring | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2024-12-13